Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model
Published on: October 6, 2023
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for
Monica Girotra1, Aaron Hansen2, Azeez Farooki1
1Endocrine Division, Department of Medicine, Weill Cornell Medical College.
Abstract:
Clinical trials in the past decade have established the antitumor effects of immune checkpoint inhibition as a revolutionary treatment for cancer. Namely, blocking antibodies to cytotoxic T-lymphocyte antigen 4 and programmed death 1 or its ligand have reached routine clinical use. Manipulation of the immune system is not without side effects, and autoimmune toxicities often known as immune-related adverse events (IRAEs) are observed. Endocrine IRAEs, such as hypophysitis, thyroid dysfunction, and insulin-dependent diabetes mellitus, can present with unique profiles that are not seen with the use of traditional chemotherapeutics. In this Review, we discuss the current hypotheses regarding the mechanism of these endocrinopathies and their clinical presentations. Further, we suggest guidelines and algorithms for patient management and future clinical trials to optimize the detection and treatment of immune checkpoint-related endocrinopathies.
Insights
Immune checkpoint inhibitors revolutionize cancer treatment but can cause endocrine immune-related adverse events (IRAEs). This review details mechanisms, presentations, and management strategies for these unique toxicities.
Area of Science:
- Immunology
- Endocrinology
- Oncology
Background:
- Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 are established cancer therapies.
- ICI treatment can lead to immune-related adverse events (IRAEs), including endocrine toxicities.
- Endocrine IRAEs present uniquely compared to traditional chemotherapy side effects.
Purpose of the Study:
- To review the mechanisms and clinical presentations of endocrine IRAEs.
- To propose management guidelines and algorithms for these conditions.
- To suggest future research directions for optimizing detection and treatment.
Main Methods:
- Literature review of clinical trials and mechanistic studies.
- Synthesis of current hypotheses on ICI-induced endocrinopathies.
- Development of evidence-based management recommendations.
Main Results:
- Endocrine IRAEs include hypophysitis, thyroid dysfunction, and diabetes mellitus.
- Mechanisms involve disruption of immune tolerance and T-cell mediated autoimmunity.
- Distinct clinical profiles necessitate specific diagnostic and management approaches.
Conclusions:
- Understanding ICI-induced endocrine IRAEs is crucial for patient safety.
- Standardized management protocols can improve patient outcomes.
- Further research is needed to refine treatment strategies and predictive biomarkers.
Related Concept Videos
Endocrine Signaling
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
What is the Endocrine System?
The Endocrine System
An Overview of the Endocrine System
The endocrine system collaborates...
Structures of the Endocrine System

